Insider Selling: Vericel Co. (NASDAQ:VCEL) CEO Sells 26,592 Shares of Stock

Vericel Co. (NASDAQ:VCEL - Get Free Report) CEO Dominick Colangelo sold 26,592 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the sale, the chief executive officer now owns 259,997 shares of the company's stock, valued at approximately $11,902,662.66. This represents a 9.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Vericel Stock Down 0.3 %

Shares of VCEL stock traded down $0.13 during trading hours on Tuesday, hitting $47.48. 222,821 shares of the company's stock traded hands, compared to its average volume of 414,911. The stock's fifty day simple moving average is $55.39 and its two-hundred day simple moving average is $51.82. Vericel Co. has a 12-month low of $39.12 and a 12-month high of $63.00. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 791.38 and a beta of 1.78.

Institutional Investors Weigh In On Vericel

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mackenzie Financial Corp bought a new stake in shares of Vericel during the fourth quarter valued at approximately $215,000. GF Fund Management CO. LTD. bought a new stake in Vericel in the 4th quarter worth approximately $57,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Vericel by 17.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 112,837 shares of the biotechnology company's stock worth $6,196,000 after purchasing an additional 16,466 shares during the period. Voloridge Investment Management LLC bought a new stake in Vericel in the 4th quarter worth approximately $1,502,000. Finally, Soleus Capital Management L.P. bought a new stake in Vericel in the 4th quarter worth approximately $4,431,000.

Remove Ads

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Truist Financial reiterated a "buy" rating and set a $61.00 target price (down from $67.00) on shares of Vericel in a report on Monday, March 3rd. BTIG Research increased their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Canaccord Genuity Group increased their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Finally, HC Wainwright restated a "buy" rating and issued a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $62.29.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.